Compare Elder Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA AJANTA PHARMA ELDER PHARMA/
AJANTA PHARMA
 
P/E (TTM) x -0.2 23.5 - View Chart
P/BV x 0.1 4.1 2.4% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ELDER PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
AJANTA PHARMA
Mar-19
ELDER PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3801,422 26.7%   
Low Rs188898 20.9%   
Sales per share (Unadj.) Rs491.2233.5 210.3%  
Earnings per share (Unadj.) Rs-3.244.0 -7.2%  
Cash flow per share (Unadj.) Rs14.452.2 27.6%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs376.5255.1 147.6%  
Shares outstanding (eoy) m20.5488.02 23.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.65.0 11.6%   
Avg P/E ratio x-89.326.4 -338.4%  
P/CF ratio (eoy) x19.722.2 88.6%  
Price / Book Value ratio x0.84.5 16.6%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m5,833102,081 5.7%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,1794,307 50.6%   
Avg. sales/employee Rs ThNM3,022.6-  
Avg. wages/employee Rs ThNM633.4-  
Avg. net profit/employee Rs ThNM569.1-  
INCOME DATA
Net Sales Rs m10,08920,554 49.1%  
Other income Rs m257211 121.7%   
Total revenues Rs m10,34620,765 49.8%   
Gross profit Rs m-7925,664 -14.0%  
Depreciation Rs m361721 50.1%   
Interest Rs m2,75612 23,761.2%   
Profit before tax Rs m-3,6535,143 -71.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,273 9.8%   
Profit after tax Rs m-653,870 -1.7%  
Gross profit margin %-7.827.6 -28.5%  
Effective tax rate %-3.424.8 -13.8%   
Net profit margin %-0.618.8 -3.4%  
BALANCE SHEET DATA
Current assets Rs m9,24011,812 78.2%   
Current liabilities Rs m9,9983,776 264.7%   
Net working cap to sales %-7.539.1 -19.2%  
Current ratio x0.93.1 29.5%  
Inventory Days Days4677 59.8%  
Debtors Days Days6082 73.5%  
Net fixed assets Rs m10,12414,398 70.3%   
Share capital Rs m206175 117.3%   
"Free" reserves Rs m5,58222,277 25.1%   
Net worth Rs m7,73422,452 34.4%   
Long term debt Rs m4,8897 74,075.8%   
Total assets Rs m22,88226,962 84.9%  
Interest coverage x-0.3444.3 -0.1%   
Debt to equity ratio x0.60 215,058.7%  
Sales to assets ratio x0.40.8 57.8%   
Return on assets %11.814.4 81.7%  
Return on equity %-0.817.2 -4.9%  
Return on capital %22.323.0 97.2%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30710,682 2.9%   
Fx outflow Rs m1252,102 6.0%   
Net fx Rs m1818,580 2.1%   
CASH FLOW
From Operations Rs m11,7543,748 313.6%  
From Investments Rs m-561-2,228 25.2%  
From Financial Activity Rs m-6,762-1,475 458.6%  
Net Cashflow Rs m4,43245 9,804.6%  

Share Holding

Indian Promoters % 39.6 73.8 53.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 1.6 483.9%  
FIIs % 16.8 7.6 221.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.0 212.4%  
Shareholders   16,479 20,968 78.6%  
Pledged promoter(s) holding % 77.6 4.4 1,766.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS